FeesSafety
Pluang+

Law firm probes Evolus over FDA warning on misleading Jeuveau ads, shares drop 7%.

Market News
04 Nov 2026, 00:58 WIB
GlobeNewsWire
View Source
Bearish
Law firm probes Evolus over FDA warning on misleading Jeuveau ads, shares drop 7%.

Pomerantz LLP is investigating claims against Evolus, Inc. following an FDA warning about misleading Instagram promotions for its wrinkle treatment Jeuveau. The FDA criticized the ads for minimizing safety risks and making exaggerated claims about the product's effectiveness. After the warning was made public on October 2, 2026, Evolus's stock price fell 7.15% to $7.14. The investigation may lead to a class action lawsuit if securities fraud or unlawful practices are confirmed.

Evolus, Inc. faces an investigation following an FDA warning about its Instagram promotions. For readers following the health sector, here is Pluang's market snapshot as of Nov 04, 2026 05:12 WIB: Out of 150 priced US health stocks, 89 rose and 58 fell. Notable movers include TXG (10X Genomics Inc) up 6.17% at USD 65.43 with 60% buy orders and a typical hold time of 92 days, BAX (Baxter International Inc) up 5.35% at USD 24.23 with 100% buy orders and a 72-day hold time, and ILMN (Illumina, Inc.) up 5.06% at USD 238.04 with balanced buy/sell orders and an 85-day hold time.

More News

Nova Klúbburinn completes share buyback, purchasing 122.7 million shares at ISK 3.26 each

Nova Klúbburinn completes share buyback, purchasing 122.7 million shares at ISK 3.26 each

Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...

Market News
Neutral
1 hour ago
DaVita faces securities fraud investigation after kidney care reform plan hits its stock.

DaVita faces securities fraud investigation after kidney care reform plan hits its stock.

Pomerantz LLP is investigating DaVita Inc. for potential securities fraud following a significant stock price drop triggered by a new federal kidney care strategy announced by the U.S. Department of Health and Human Services. The plan aims to increas...

Market News
Bearish
5 hours ago
3M commits $5.8B through 2034 to settle PFAS injury claims, cutting litigation risks significantly.

3M commits $5.8B through 2034 to settle PFAS injury claims, cutting litigation risks significantly.

3M has agreed to a $7.35 billion nominal settlement, with a present value of $5.8 billion, to resolve approximately 99% of PFAS-related personal injury claims involving up to 120,000 plaintiffs. This settlement reduces litigation uncertainty and alig...

Market News
Neutral
5 hours ago
Neogen faces investigation after FDA links its sterile product to horse deaths, causing stock to drop 7%.

Neogen faces investigation after FDA links its sterile product to horse deaths, causing stock to drop 7%.

Pomerantz LLP is investigating Neogen Corporation following an FDA warning about its veterinary wound care product, Neogen Vet HYCOAT, which was linked to serious infections and at least 20 horse deaths. This represents the largest number of horse de...

Market News
Bearish
5 hours ago
AMC to report Q3 earnings amid rising North American box-office revenue

AMC to report Q3 earnings amid rising North American box-office revenue

AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...

Market News
Neutral
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App